Applications of 5-[4-((3-Chloro-4-((3-Fluorobenzyl)Oxy)Phenyl)Amino)Quinazolin-6-Yl]-2-Furaldehyde in Industrial Manufacturing

5-[4-((3-Chloro-4-((3-Fluorobenzyl)Oxy)Phenyl)Amino)Quinazolin-6-Yl]-2-Furaldehyde serves as an advanced intermediate in the synthesis of specialty pharmaceuticals and complex agrochemicals. Its well-defined chemical structure enables precision modification of downstream products within highly regulated sectors, with particular relevance in life science APIs, crop protection actives, specialty dye molecules, and diagnostic reagents. Below, we detail its integration in industrial-scale manufacturing across key application fields based on current commercial utilization.

1. Targeted Oncology Active Pharmaceutical Ingredient Synthesis

This compound acts as a core intermediate in the multistep synthesis of clinical-stage kinase inhibitors used for targeted cancer therapies. It provides the quinazoline scaffold with functional groups essential for receptor binding specificity. Manufacturers implement rigorous in-process controls at this stage, given its direct conversion into regulated drug substances for human administration. The compound’s purity profile, moisture limits, and trace impurity control require validation against ICH Q7A guidelines. End-to-end documentation supports API batch traceability and regulatory filings.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• US FDA 21 CFR Part 210/211 (cGMP for finished pharmaceuticals)
• EU EudraLex Volume 4 (GMP for APIs)
• Ph. Eur. Monographs for oncology APIs

Typical usage ratio

• Employ at 0.8 to 1.4 molar equivalents in the coupling condensation stage; ratio adjusted based on substitution pattern of the N-heterocycle target

Downstream process integration

• Added at the penultimate step through Buchwald-Hartwig amination or related Pd-catalyzed arylation, followed by cyclization and purification stages

Final product types

• Oral kinase inhibitor film-coated tablets (e.g., EGFR, ALK, or HER2 targeted drugs)
• API crystalline powders for formulation into injectables
• Research-use oncology inhibitors in pilot-scale lots

2. Agrochemical Active Ingredient Intermediate for Herbicides

Industrial synthesis routes for certain novel post-emergent herbicides employ this intermediate due to selective inhibition characteristics required for broadleaf weed control. It enters the process immediately before side-chain functionalization, enabling downstream modification for tailored soil persistence. QA procedures conform to agrochemical regulatory requirements to guarantee environmental and worker safety, emphasizing batch homogeneity and trace-level impurity limits as set by international crop protection authorities.

Industry compliance standards

• FAO Specification for Plant Protection Products
• OECD Guidelines for the Testing of Chemicals
• ISO 9001:2015 Quality Management System (applicable to agrochemical production)
• REACH (Registration, Evaluation and Authorisation of Chemicals, EU)

Typical usage ratio

• Used at 5–18% by mole in key condensation or etherification steps within active ingredient synthesis; varies by seasonal product target and plant species tolerance

Downstream process integration

• Introduced post-core scaffold assembly via nucleophilic aromatic substitution, then proceeds to protection/deprotection sequence before formulation

Final product types

• Technical grade active for suspension concentrate (SC) and water dispersible granule (WDG) formulations
• Finished herbicide products for commercial agricultural use
• Reference standards for field-application residue analysis

3. Precursor for Specialty Quinazoline Dyes and Fluorescent Labels

Chemical synthesis teams employ this compound as a tailored starting scaffold when producing fluorescent dyes and specialty labeling reagents. Its electron-withdrawing and donating substituents allow fine-tuning of quantum yields and emission maxima, essential for high-sensitivity assays in clinical diagnostics, analytical chemistry, and molecular biology. Manufacturing processes must validate absence of residual toxic impurities and ensure photostability per analytical reagent norms.

Industry compliance standards

• ISO 17034 Reference Material Production
• USP <1040> Analytical Reagents
• Directive 2011/65/EU (RoHS for laboratory chemicals)
• EU Regulation (EC) No 1907/2006 (REACH)

Typical usage ratio

• Introduced at 0.3–0.7 molar equivalents depending on dye backbone and substituent reactivity for colorant/highlighter development

Downstream process integration

• Condensed with specific amine or halide reagents under controlled temperature/light conditions to form stable chromophores, then purified for reactivity assessment

Final product types

• Water-soluble fluorescent dye powders
• Analytical reference solutions for diagnostic kits
• Surface marker labeling compounds used in flow cytometry and bioimaging

4. Intermediate for Diagnostic Reagent Synthesis

Manufacturers of medical diagnostic kits utilize this compound in the synthesis of enzyme-linked reagents and selective affinity probes. It’s incorporated to provide specificity in ligand or protein binding assays. Strict documentation and validation accompany each batch, aligned with in-vitro diagnostic directive requirements. All production adheres to cleanroom and cross-contamination prevention protocols due to later use in clinical settings.

Industry compliance standards

• ISO 13485:2016 Medical Devices – Quality Management Systems for IVDs
• IVDR (EU) 2017/746 on in vitro diagnostic medical devices
• Good Laboratory Practice (GLP, OECD)
• CLSI (Clinical and Laboratory Standards Institute) Protocols

Typical usage ratio

• Typically 0.5–1.2 mole equivalent, modulated based on detection sensitivity and cross-reactivity studies in the probe synthesis workflow

Downstream process integration

• Reacted in the conjugation phase with enzyme linkers or target-binding moieties, followed by HPLC purification and lyophilization

Final product types

• Conjugated chemiluminescent or colorimetric probes for immunoassays
• Clinical reference standards for laboratory analyzers
• Labeled antibodies for hospital diagnostic kits